“…2,27 We also considered 6 bronchodilator response (BDR) at any visit, most often the baseline, defined as an increase in either FEV 1 or FVC of at least 12% and 200 mL in response to inhaled albuterol administration 7,10 ; body mass index (BMI) in kilograms per square meter measured at the baseline visit 8 ; weight gain (as indicated by longitudinal measured BMI trajectory (BMIslope) in kilograms per square meter per year 10 ). Lastly, from the QCT data, 9 total lung volume (TLV CT ), with calculated predicted values 28 and assessed by z scores, 10 lung attenuation volume percent, either high (HAV% from −600 to −250 Hounsfield units [HU], with >10% as cut point) and low (LAV% less than −950 HU, low attenuation volume percent, with >2.5% as cut point), 4,29 indirect distal airway measurements such as 11 end-expiratory air trapping at −856 HU (AT EXP 856), 8,29 and 12 mean expiratory:inspiratory lung density ratio (MLD EI ), 8 and proximal airway metrics such as 13 wall area percent (WAP) directly measured on the third generation of the right upper lobe, 8,10,29 and 14 Pi10, the average wall thickness of a hypothetical airway with a 10-mm luminal perimeter on CT. 29,30 As in previous studies of longitudinal lung function trajectories among participants in the Mount Sinai WTC GRC cohort, 4,10 we conducted a secondary analysis of the FEV 1 trajectories for the resulting clusters. As in previous work, 4 we estimated the longitudinal FEV 1 slopes for each subject with at least 3 good quality (as defined previously) spirometries performed between July 2002 and December 2018, and used them to define the following three trajectories as follows: rapid FEV 1 decline ("rapid decliner") by an FEV 1 slope < −66.5 mL/y (ie, less than the group mean-0.5 SD), FEV 1 gain ("gainer") by an FEV 1 slope > 0 mL/y, and intermediate FEV 1 decline ("intermediate decliner") by an FEV 1 slope between 0 and −66.5 mL/y (ie, between 0 and the group mean-0.5 SD).…”